Ferroptosis-centered Disease Response Information
General Information of the Disease (ID: DIS00122)
Name |
Intervertebral disc degeneration
|
||||
---|---|---|---|---|---|
ICD |
ICD-11: FA80
|
Full List of Target(s) of This Ferroptosis-centered Disease
Unspecific Target
In total 6 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | ||||
Responsed Disease | Intervertebral disc degeneration [ICD-11: FA80] | ||||
Responsed Drug | Hesperidin | Approved | |||
Responsed Regulator | Transcription factor p65 (RELA) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
NF-kappa B signaling pathway | hsa04064 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | hNPCs (Human nucleus pulposus cells) | ||||
In Vivo Model |
Male C57BL/6 mice (10-12 weeks) were devoted to generate needle puncture-induced intervertebral disc degeneration model. For intervertebral disc degeneration (IVDD) treatment, hesperidin was administratedorally and the dose was calculated in reference to previous studies using themetrological conversion formula between human and mouse. The dosein mice is = 5.5 mg/kg x 70 kg x 0.0026/20g = 9.1 x 5.5 mg/kg = 50.05 mg/kg ~50 mg/kg.
Click to Show/Hide
|
||||
Response regulation | The current study proved for the first time that Hesperidin may protect HNP cells from degeneration by suppressing ferroptosis in an oxidative stress-dependent via enhancing the expression of Nrf2 and suppressing the NF-kB pathway. The evidence will provide a possible basis for future targeted treatment for intervertebral disc degeneration. | ||||
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [6] | ||||
Responsed Disease | Intervertebral disc degeneration [ICD-11: FA80] | ||||
Responsed Regulator | Mitochondrial import inner membrane translocase subunit Tim9 (TIMM9) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | hNPCs (Human nucleus pulposus cells) | ||||
Response regulation | Ferroptosis and immune infiltration play an important role in the pathogenesis of intervertebral disc degeneration (IDD). Seven key differentially expressed FRGs (DE-FRGs) were screened, including the upregulated genes NOX4 and PIR, and the downregulated genes TIMM9, ATF3, ENPP2, FADS2 and TFAP2A. | ||||
Experiment 3 Reporting the Ferroptosis-centered Disease Response by This Target | [7] | ||||
Responsed Disease | Intervertebral disc degeneration [ICD-11: FA80] | ||||
Responsed Regulator | Early growth response protein 1 (EGR1) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
NF-kappa B signaling pathway | hsa04064 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | hCEPs (Human cartilage endplate cells) | ||||
In Vivo Model |
24 male C57BL/6J mice (8 weeks, weighing 20 ± 2 g) were purchased from Charles River (Beijing, China). Mice were anesthetized via an intraperitoneal injection of 3% pentobarbital sodium (40 mg/kg). Afterward, their extraperitoneal space was isolated and the exterior part of IVD was exposed. A 26 G puncture needle (90% of intervertebral space height) was utilized to punch in the C6/C7 IVD at a depth of 2.5 mm. The puncture needle was inserted into the dorsal annulus fibrosus across the center of the nucleus pulposus and partially across the ventral annulus fibrosus and withdrawn 30 s later.
Click to Show/Hide
|
||||
Response regulation | In Intervertebral disc degeneration (IVDD) cell models, EGR1 knockdown reduced ferroptosis and cartilage degeneration, which was reversed by MAP3K14 overexpression or Erastin treatment. Collectively, EGR1 promoted ferroptosis and IVD cartilage degeneration through MAP3K14-NF-B axis. | ||||
Experiment 4 Reporting the Ferroptosis-centered Disease Response by This Target | [7] | ||||
Responsed Disease | Intervertebral disc degeneration [ICD-11: FA80] | ||||
Responsed Regulator | Mitogen-activated protein kinase kinase kinase 14 (MAP3K14) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
NF-kappa B signaling pathway | hsa04064 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | hCEPs (Human cartilage endplate cells) | ||||
In Vivo Model |
24 male C57BL/6J mice (8 weeks, weighing 20 ± 2 g) were purchased from Charles River (Beijing, China). Mice were anesthetized via an intraperitoneal injection of 3% pentobarbital sodium (40 mg/kg). Afterward, their extraperitoneal space was isolated and the exterior part of IVD was exposed. A 26 G puncture needle (90% of intervertebral space height) was utilized to punch in the C6/C7 IVD at a depth of 2.5 mm. The puncture needle was inserted into the dorsal annulus fibrosus across the center of the nucleus pulposus and partially across the ventral annulus fibrosus and withdrawn 30 s later.
Click to Show/Hide
|
||||
Response regulation | In Intervertebral disc degeneration (IVDD) cell models, EGR1 knockdown reduced ferroptosis and cartilage degeneration, which was reversed by MAP3K14 overexpression or Erastin treatment. Collectively, EGR1 promoted ferroptosis and IVD cartilage degeneration through MAP3K14-NF-B axis. | ||||
Experiment 5 Reporting the Ferroptosis-centered Disease Response by This Target | [8] | ||||
Responsed Disease | Intervertebral disc degeneration [ICD-11: FA80] | ||||
Responsed Regulator | Ubiquitin carboxyl-terminal hydrolase 11 (USP11) | Suppressor | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Ubiquitin mediated proteolysis | hsa04120 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | |
HNP (Human nucleus pulposus cells) | |||||
In Vivo Model |
8-10 weeks old male mice were placed in prone position and anesthetized with isoflurane inhalation. The 1.5 cm-long longitudinal incision was made in 2 mm from the posterior midline. The superior and inferior articular processes, supraspinous ligament and interspinous ligament of the L4-L5 lumbar vertebrae were removed to construct LSI, which would induce IVDD. After the operation, the mice were placed in a warm environment.
Click to Show/Hide
|
||||
Response regulation | Overexpression of USP11 significantly ameliorate oxidative stress-induced ferroptosis, thus relieving intervertebral disc degeneration (IVDD) by increasing Sirt3. Moreover, knockout of USP11 in vivo (USP11) resulted in exacerbated IVDD and poor pain-related behavioral scores, which could be reversed by overexpression of Sirt3 in intervertebral disc. | ||||
Experiment 6 Reporting the Ferroptosis-centered Disease Response by This Target | [8] | ||||
Responsed Disease | Intervertebral disc degeneration [ICD-11: FA80] | ||||
Responsed Regulator | NAD-dependent protein deacetylase sirtuin-3, mitochondrial (SIRT3) | Suppressor | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Ubiquitin mediated proteolysis | hsa04120 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | |
HNP (Human nucleus pulposus cells) | |||||
In Vivo Model |
8-10 weeks old male mice were placed in prone position and anesthetized with isoflurane inhalation. The 1.5 cm-long longitudinal incision was made in 2 mm from the posterior midline. The superior and inferior articular processes, supraspinous ligament and interspinous ligament of the L4-L5 lumbar vertebrae were removed to construct LSI, which would induce IVDD. After the operation, the mice were placed in a warm environment.
Click to Show/Hide
|
||||
Response regulation | Overexpression of USP11 significantly ameliorate oxidative stress-induced ferroptosis, thus relieving intervertebral disc degeneration (IVDD) by increasing Sirt3. Moreover, knockout of USP11 in vivo (USP11) resulted in exacerbated IVDD and poor pain-related behavioral scores, which could be reversed by overexpression of Sirt3 in intervertebral disc. | ||||
Transferrin receptor protein 2 (TFR2)
In total 2 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [2] | |||
Target for Ferroptosis | Driver | |||
Responsed Disease | Intervertebral disc degeneration [ICD-11: FA80] | |||
Responsed Regulator | Circ_STC2 (circRNA) | Driver | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model | hNPCs (Human nucleus pulposus cells) | |||
Response regulation | Circ-STC2 and TFR2 expressions were up-regulated in intervertebral disc degeneration (IDD) tissues, and miR-486-3p expression was down-regulated. Circ-STC2 inhibits the cell viability, induced the ferroptosis of the TBHP treated NPCs via targeting miR-486-3p/TFR2 axis. | |||
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [2] | |||
Target for Ferroptosis | Driver | |||
Responsed Disease | Intervertebral disc degeneration [ICD-11: FA80] | |||
Responsed Regulator | hsa-miR-486-3p (miRNA) | Suppressor | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model | hNPCs (Human nucleus pulposus cells) | |||
Response regulation | Circ-STC2 and TFR2 expressions were up-regulated in intervertebral disc degeneration (IDD) tissues, and miR-486-3p expression was down-regulated. Circ-STC2 inhibits the cell viability, induced the ferroptosis of the TBHP treated NPCs via targeting miR-486-3p/TFR2 axis. | |||
Solute carrier family 40 member 1 (SLC40A1)
In total 1 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [3] | |||
Target for Ferroptosis | Marker/Suppressor | |||
Responsed Disease | Intervertebral disc degeneration [ICD-11: FA80] | |||
Responsed Regulator | hsa-miR-10a-5p (miRNA) | Suppressor | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | |||
In Vitro Model | hCDs (Chondrocytes) | |||
Response regulation | Inflammatory cytokine IL-6 appeared in Intervertebral disc degeneration (IDD) aggravates its degeneration by inducing cartilage cell ferroptosis. This is caused partially by inhibiting miR-10a-5p and subsequently derepressing IL-6R signaling pathway. The ferroptosis-inhibitory effect exhibited by overexpressing miR-10a-5p was achieved by promoting GPX4 and ferroportin-1 (FPN1) but suppressing divalent metal transporter 1 (DMT1) expression in IL-6-treated cartilage cells. | |||
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
In total 2 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [4] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Intervertebral disc degeneration [ICD-11: FA80] | ||||
Responsed Drug | L-Homocysteine | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Apoptosis | hsa04210 | ||||
Necroptosis | hsa04217 | ||||
Cell Process | Cell ferroptosis | ||||
Cell apoptosis | |||||
Cell necrosis | |||||
In Vitro Model | hNPCs (Human nucleus pulposus cells) | ||||
In Vivo Model |
Thirty male C57BL/6 mice (8 weeks old, average weight 25 g) were divided into three groups. Blank group: Ten mice were fed with normal diet and water. HHcy group: Ten mice were fed with a high Met diet (normal diet with 2% l-methionine). HHcy + Folic Acidrescue group: Ten mice were fed withhigh Met diet (normal diet with 2% l-methionine), and injected with Folic Acid (1.0 umol/kg/d) twice a week two months later. At the beginning of treatment, mice were anesthetized with anintraperitoneal injectionof 0.3% (w/v)pentobarbital sodium(20 uL/g) before surgery and disc degeneration was induced by stabbing the C5-6 and C6-7 discs with a 32G needle.
Click to Show/Hide
|
||||
Response regulation | Homocysteine (Hcy) is an amino acid involved in gene methylation. Hcy upregulates oxidative stress and ferroptosis in the nucleus pulposus via enhancing GPX4 methylation, and is a new contributing factor in intervertebral disc degeneration (IVDD). | ||||
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [3] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Intervertebral disc degeneration [ICD-11: FA80] | ||||
Responsed Regulator | hsa-miR-10a-5p (miRNA) | Suppressor | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | hCDs (Chondrocytes) | ||||
Response regulation | Inflammatory cytokine IL-6 appeared in Intervertebral disc degeneration (IDD) aggravates its degeneration by inducing cartilage cell ferroptosis. This is caused partially by inhibiting miR-10a-5p and subsequently derepressing IL-6R signaling pathway. The ferroptosis-inhibitory effect exhibited by overexpressing miR-10a-5p was achieved by promoting GPX4 and ferroportin-1 (FPN1) but suppressing divalent metal transporter 1 (DMT1) expression in IL-6-treated cartilage cells. | ||||
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
In total 3 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | ||||
Target for Ferroptosis | Marker/Suppressor | ||||
Responsed Disease | Intervertebral disc degeneration [ICD-11: FA80] | ||||
Responsed Drug | Hesperidin | Approved | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
NF-kappa B signaling pathway | hsa04064 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | hNPCs (Human nucleus pulposus cells) | ||||
In Vivo Model |
Male C57BL/6 mice (10-12 weeks) were devoted to generate needle puncture-induced intervertebral disc degeneration model. For intervertebral disc degeneration (IVDD) treatment, hesperidin was administratedorally and the dose was calculated in reference to previous studies using themetrological conversion formula between human and mouse. The dosein mice is = 5.5 mg/kg x 70 kg x 0.0026/20g = 9.1 x 5.5 mg/kg = 50.05 mg/kg ~50 mg/kg.
Click to Show/Hide
|
||||
Response regulation | Hesperidin may protect HNP cells from degeneration by suppressing ferroptosis in an oxidative stress-dependent via enhancing the expression of Nrf2 and suppressing the NF-B pathway. The evidence will provide a possible basis for future targeted treatment for intervertebral disc degeneration. | ||||
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [5] | ||||
Target for Ferroptosis | Marker/Suppressor | ||||
Responsed Disease | Intervertebral disc degeneration [ICD-11: FA80] | ||||
Responsed Regulator | Circ_0072464 (circRNA) | Suppressor | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | hBMCs (Bone marrow cells) | ||||
hBMSCs (Bone marrow stromal cells) | |||||
Response regulation | BMSC-EV-loaded circ_0072464 inhibited NPC ferroptosis to relieve intervertebral disc degeneration (IDD) via upregulation of miR-431-mediated NRF2, therefore providing a potential therapeutic target against IDD. | ||||
Experiment 3 Reporting the Ferroptosis-centered Disease Response by This Target | [5] | ||||
Target for Ferroptosis | Marker/Suppressor | ||||
Responsed Disease | Intervertebral disc degeneration [ICD-11: FA80] | ||||
Responsed Regulator | hsa-miR-431-3p (miRNA) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | hBMCs (Bone marrow cells) | ||||
hBMSCs (Bone marrow stromal cells) | |||||
Response regulation | BMSC-EV-loaded circ_0072464 inhibited NPC ferroptosis to relieve intervertebral disc degeneration (IDD) via upregulation of miR-431-mediated NRF2, therefore providing a potential therapeutic target against IDD. | ||||
Natural resistance-associated macrophage protein 2 (SLC11A2)
In total 1 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [3] | |||
Target for Ferroptosis | Driver | |||
Responsed Disease | Intervertebral disc degeneration [ICD-11: FA80] | |||
Responsed Regulator | hsa-miR-10a-5p (miRNA) | Suppressor | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | |||
In Vitro Model | hCDs (Chondrocytes) | |||
Response regulation | Inflammatory cytokine IL-6 appeared in Intervertebral disc degeneration (IDD) aggravates its degeneration by inducing cartilage cell ferroptosis. This is caused partially by inhibiting miR-10a-5p and subsequently derepressing IL-6R signaling pathway. The ferroptosis-inhibitory effect exhibited by overexpressing miR-10a-5p was achieved by promoting GPX4 and ferroportin-1 (FPN1) but suppressing divalent metal transporter 1 (DMT1) expression in IL-6-treated cartilage cells. | |||
References